Advance amount related to milestone payment.

No definition available.

Name:	LIXT_AdvanceAmountRelatedToMilestonePayment
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount related to milestone payment.

+ References

No definition available.

+ Details

Name:	LIXT_AmountRelatedToMilestonePayment
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Consulting and advisory quarterly cash fee.

+ References

No definition available.

+ Details

Name:	LIXT_ConsultingAndAdvisoryCashFee
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Estimated work cost.

+ References

No definition available.

+ Details

Name:	LIXT_EstimatedWorkCost
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of expected paymen through software.

+ References

No definition available.

+ Details

Name:	LIXT_ExpectedPaymentThroughSoftware
Namespace Prefix:	LIXT_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Expected payment in services.

+ References

No definition available.

+ Details

Name:	LIXT_ExpectedPaymentinServices
Namespace Prefix:	LIXT_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Reimbursement expense.

+ References

No definition available.

+ Details

Name:	LIXT_ReimbursementExpense
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalty payable.

+ References

No definition available.

+ Details

Name:	LIXT_RoyaltyPayable
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Royaties percentage

+ References

No definition available.

+ Details

Name:	LIXT_RoyatiesPercentage
Namespace Prefix:	LIXT_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Work order agreement costs

+ References

No definition available.

+ Details

Name:	LIXT_WorkOrderAgreementCosts
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	us-gaap_ContractualObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Name:	us-gaap_DeferredCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Total expenses of a HCO before stop-loss insurance recoveries. Costs of services rendered (including costs of services rendered but not yet reported).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 954
-SubTopic 450
-Section 30
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478201/954-450-30-4

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 954
-SubTopic 450
-Section 30
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478201/954-450-30-3

+ Details

Name:	us-gaap_HealthCareOrganizationHealthCareCostsGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date for elements of machinery or equipment held for the purpose of replacing similar parts in the course of repair or maintenance.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 330
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_InventoryPartsAndComponentsNetOfReserves
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(6))
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_LitigationSettlementExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash paid for royalties during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of noncash expense for share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:	us-gaap_ShareBasedCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsAndClinicalTrialMonitoringAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialMonitoringAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=LIXT_Phase1bMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=LIXT_Phase2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchMonitoringMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MDAndersonCancerCenterClinicalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=LIXT_DueEachJanuaryOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details Narrative)								1 Months Ended	3 Months Ended		9 Months Ended
Commitments and Contingencies (Details Narrative)	Jul. 08, 2024 USD ($)	Feb. 23, 2024 USD ($)	Aug. 27, 2023 USD ($)	Jun. 22, 2023 USD ($)	Feb. 05, 2021 USD ($)	Sep. 14, 2015 USD ($)	Dec. 24, 2013 USD ($)	Apr. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jan. 31, 2030 USD ($)	Dec. 31, 2023 USD ($)	Oct. 03, 2023 EUR (€)	Oct. 08, 2021 EUR (€)
Other Commitments [Line Items]
Total costs									$ 6,928		$ 6,928
Research and development costs									361,630	$ 132,487	691,402	$ 749,029
Aggregate commitments expected									3,616,000		3,616,000
GEIS [Member]
Other Commitments [Line Items]
Amount related to milestone payment											684,652
NDA Consulting Corp [Member]
Other Commitments [Line Items]
Consulting and advisory fee							$ 4,000		4,000	4,000	12,000	12,000
Clinical Trial Agreements And Clinical Trial Monitoring Agreements [Member]
Other Commitments [Line Items]
Contractual commitment									3,918,000		3,918,000
Clinical Trial Agreements [Member]
Other Commitments [Line Items]
Contractual commitment									3,616,000		3,616,000
Clinical Trial Monitoring Agreements [Member]
Other Commitments [Line Items]
Contractual commitment									302,000		302,000
Aggregate commitments expected									78,000		78,000
Clinical Research Support Agreement [Member] \| City of Hope [Member]
Other Commitments [Line Items]
Litigation settlement expense	$ 207,004								207,004	0	285,019	69,001
Total costs									732,532		732,532
Collaboration Agreement [Member] \| GEIS [Member]
Other Commitments [Line Items]
Inventory costs														$ 1,144,000
Research and development costs									0	268,829
Aggregate commitments expected									3,616,000		3,616,000
Collaboration Agreement [Member] \| GEIS [Member] \| Phase 1b [Member]
Other Commitments [Line Items]
Aggregate commitments expected									284,000		284,000
Collaboration Agreement [Member] \| GEIS [Member] \| Phase 2 [Member]
Other Commitments [Line Items]
Aggregate commitments expected									3,332,000		3,332,000
Collaboration Agreement [Member] \| Bio Pharma Works LLC [Member]
Other Commitments [Line Items]
Consulting and advisory fee						$ 10,000
Reimbursed expense									8,000	30,000	35,200	90,000
Clinical Trial Research Agreement [Member]
Other Commitments [Line Items]
Aggregate commitments expected									147,239		147,239
Clinical Trial Research Monitoring [Member]
Other Commitments [Line Items]
Research and development costs									12,610		20,838
Aggregate commitments expected									106,380		106,380
Work order agreement costs									95,000		95,000
Clinical Trial Research Monitoring [Member] \| MD Anderson Cancer Center Clinical [Member]
Other Commitments [Line Items]
Aggregate commitments expected									20,838		20,838
Clinical Trial Research Monitoring [Member] \| Theradex Systems, Inc. [Member]
Other Commitments [Line Items]
Research and development costs									14,900		14,900
Work Order Agreement [Member]
Other Commitments [Line Items]
Total costs									41,070		41,070
Aggregate commitments expected									118,000		118,000
Work Order Agreement [Member] \| City of Hope [Member]
Other Commitments [Line Items]
Total costs									89,284		89,284
Research and development costs					$ 335,000				1,603	4,500	10,603	15,740
Work Order Agreement [Member] \| Theradex Systems, Inc. [Member]
Other Commitments [Line Items]
Total costs									14,900		14,900
Research and development costs									13,475	3,750	26,208	10,000
Work cost			$ 106,380	$ 153,000
Percentage of payment through services			47.00%	72.00%
Percentage of payment through software			53.00%	28.00%
License Agreement [Member]
Other Commitments [Line Items]
Non refundable license issue royalty		$ 50,000
Dosing of product		100,000
Payment for royalties		$ 1,225,000
Royalty percentage		5.00%
License Agreement [Member] \| Minimum [Member]
Other Commitments [Line Items]
Non refundable license issue royalty								$ 50,000
License Agreement [Member] \| Due Each January 1 [Member]
Other Commitments [Line Items]
Minimum annual royalty payable		$ 25,643						$ 25,643					$ 30,000
Licensing Agreements [Member]
Other Commitments [Line Items]
Research and development costs											68,106
Aggregate commitments expected									1,795,000		1,795,000
Research and development process costs									7,537		68,106
Stock based compensation										21,507		9,109
Development Collaboration Agreement [Member] \| Netherlands Cancer Institute [Member]
Other Commitments [Line Items]
Research and development costs											695,918
Aggregate commitments expected									279,000		279,000				€ 500,000	€ 391,000
Advance amount related to milestone payment									76,278	51,568	210,362	156,950
MRI Global [Member]
Other Commitments [Line Items]
Research and development costs											334,147
Aggregate commitments expected									124,000		124,000
Advance amount related to milestone payment									$ 9,062	$ 21,045	$ 18,932	$ 30,628